Please ensure Javascript is enabled for purposes of website accessibility

Will Your Elective Surgery Be Delayed by Coronavirus?

By Mark Prvulovic - Updated Mar 16, 2020 at 10:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Health groups are asking hospitals to decrease or even halt elective surgeries as the coronavirus pandemic heats up.

As America prepares for what seems to be an inevitable influx of COVID-19 patients over the coming weeks, many medical providers are concerned that there won't be enough ICU beds and ventilators to treat these new cases. Over the weekend, U.S. Surgeon General Jerome Adams called on healthcare and hospital companies to consider halting all elective surgeries.

Instead, the Surgeon General called on U.S. hospitals to conserve medical resources and further prepare for a surge in COVID-19 patients that could overwhelm the healthcare system. Such is the case in countries like Italy, where the number of COVID-19 patients has swelled to over 25,000 on Monday. 

Multiple hospital beds lined up in a hospital room.

Image source: Getty Images.

Some hospital associations responded by pushing back against the request, citing that certain important surgeries like removing a cancerous tumor or replacing a faulty heart valve fall under the classification of elective surgeries as well. For the most part, however, curtailing at least some of the less important elective surgeries seems like a no-brainer. The Massachusetts Department of Public Health issued an official order on Sunday requiring that "hospitals much cancel non-essential elective procedures," to prepare for COVID-19.

Wider implications

Patients who need elective surgeries that aren't potentially life-threatening will likely be postponed to an unspecified later date. Some major hospital stocks, such as HCA Healthcare, have seen their share prices plunge over the past month or so. On the other hand, biotech stocks working on a COVID-19 treatment, such as Gilead Sciences as well as niche companies like telehealth provider Teladoc, has seen their shares rise significantly.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.83 (-0.40%) $0.25
HCA Healthcare, Inc. Stock Quote
HCA Healthcare, Inc.
$179.82 (-1.38%) $-2.51
Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$37.46 (0.78%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.